Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing first‑, second‑and third‑generation EGFR‑TKIs
AK Vaid, A Gupta, G Momi - … journal of oncology, 2021 - spandidos-publications.com
Abstract A substantial (40‑60%) proportion of patients with non‑small cell lung carcinoma
(NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic …
(NSCLC) have epidermal growth factor receptor (EGFR) mutations, a crucial therapeutic …
Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: a real-world multicentric cohort analysis from India
A Garg, U Batra, P Choudhary, D Jain… - Current Problems in …, 2020 - Elsevier
Background: The development of various targeted therapies against Epidermal Growth
Factor Receptor (EGFR) has been a major step in therapeutic advancements in lung cancer …
Factor Receptor (EGFR) has been a major step in therapeutic advancements in lung cancer …
Re‐biopsy and liquid biopsy for patients with non‐small cell lung cancer after EGFR‐tyrosine kinase inhibitor failure
J Zhou, C Zhao, J Zhao, Q Wang, X Chu, J Li… - Thoracic …, 2019 - Wiley Online Library
Background Re‐biopsy is important for exploring resistance mechanisms, especially for non‐
small cell lung cancer (NSCLC) patients who develop resistance to EGFR‐tyrosine kinase …
small cell lung cancer (NSCLC) patients who develop resistance to EGFR‐tyrosine kinase …
All-in-one approaches for rapid and highly specific quantifcation of single nucleotide polymorphisms based on ligase detection reaction using molecular beacons as …
W Zhang, K Liu, P Zhang, W Cheng, Y Zhang, L Li… - Talanta, 2021 - Elsevier
Rapid, simple, specific and sensitive approaches for single nucleotide polymorphisms
(SNPs) detection are essential for clinical diagnosis. In this study, all-in-one approaches …
(SNPs) detection are essential for clinical diagnosis. In this study, all-in-one approaches …
High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third‐generation TKI outcomes
Y Li, F Zhang, P Yuan, L Guo, Y Jianming… - Thoracic Cancer, 2020 - Wiley Online Library
Background Clinical detection of EGFR‐TKI resistance mechanism through tissue can be
really challenging due to risks associated with the procedure. Thus, liquid biopsy, especially …
really challenging due to risks associated with the procedure. Thus, liquid biopsy, especially …
[HTML][HTML] Phase III randomized controlled trial of gefitinib versus chemotherapy in EGFR-positive treatment-naïve metastatic lung cancer: Long-term outcome after eight …
A Singh, V Patil, N Menon, S More, S Jain… - Cancer Research …, 2024 - journals.lww.com
Background: This was the first Phase III randomized study comparing an epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib, to standard-of-care …
factor receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib, to standard-of-care …
The Presence of EGFR T790M in TKI-Naive Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare
W Li, K Kok, GW Tan, P Meng, M Mastik, N Rifaela… - Cancers, 2022 - mdpi.com
Simple Summary Treatment outcomes for non-small cell lung cancer (NSCLC) patients have
significantly improved since the introduction of targeted therapy using tyrosine kinase …
significantly improved since the introduction of targeted therapy using tyrosine kinase …
[HTML][HTML] T790M mutation and clinical outcomes with osimertinib in patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer
R Jaiswal, R Pinninti, MVTK Mohan… - Indian Journal of …, 2019 - thieme-connect.com
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors TKIs) are
highly effective in EGFR-mutant advanced lung cancer. The most common resistance …
highly effective in EGFR-mutant advanced lung cancer. The most common resistance …
First-line treatment of EGFR-mutant NSCLC: spoiled for choice?
U Batra, M Sharma, S Joga, P Jain - Cancer Research, Statistics …, 2019 - journals.lww.com
2. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al.
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med …
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med …
[HTML][HTML] Scar tissue to lung cancer; pathways and treatment
Lung cancer still remains diagnosed at a late stage although we have novel diagnostic
techniques at our disposal. However; for metastatic disease we have novel therapies based …
techniques at our disposal. However; for metastatic disease we have novel therapies based …